GlaxoSmithKline is one of three drug manufacturers that recently announced refunds for 340B overcharges.

GlaxoSmithKline, Exelan, and BioMarin Issue 340B Refunds

Three drug manufacturers recently announced they are refunding 340B overpayments to covered entities, part of a growing number of companies that have disclosed they miscalculated the pricing of their products.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report